American Society of Clinical Oncology 2013: Boehringer Ingelheim Pharmaceuticals, Inc. to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RIDGEFIELD, Conn., May 15, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced the upcoming presentation of data from 14 abstracts involving three of the company's investigational oncology compounds – afatinib*, nintedanib* and volasertib*. Results – to be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2013 – are from Boehringer Ingelheim's robust oncology pipeline and demonstrate the company's commitment to the oncology community and patients through the research and development of new anti-cancer compounds.

Help employers find you! Check out all the jobs and post your resume.

Back to news